Article
Molecular alterations in triple-negative breast cancer-the road to new treatment strategies.
Lancet (London, England) - 17 Jun 2017
Denkert Carsten, Liedtke Cornelia, Tutt Andrew, von Minckwitz Gunter
Abstract excerpt
Triple-negative breast cancer is a heterogeneous disease and specific therapies have not been available for a long time. Therefore, conventional chemotherapy is still considered the clinical state of the art. Different subgroups of triple-negative breast cancer have been identified on the basis of protein expression, mRNA signatures, and genomic alterations. Important elements of triple-negative breast cancer...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.